Hims & Hers Stock Pops After Massive Acquisition
Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Hims & Hers' business grew by more than 50% last quarter. The company has plenty more growth opportunities to pursue in pain management, fertility, and diabetes.
Is Hims & Hers Health the Next Teladoc?
Demand for telemedicine services boomed during the pandemic lockdowns. Teladoc stock price soared more than 250%, only to plunge.
Invest While You Can: Pullbacks on These 3 Stocks Won't Last Long
Traders are often quoted as slaves to volatility, as their entire business model is dependent on stocks moving actively to meet the conditions of a trade and spread. However, long-term value investors are just as dependent on volatility as their distant day-trader counterparts.
Is Hims & Hers Health Stock a Buy?
Hims & Hers stock price has plummeted in recent weeks. Share prices no longer reflect GLP-1 hype.
Hims & Hers Stock Plunges 32.1% in Three Months: What's Next?
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Has Eli Lilly Destroyed Hims & Hers Upside?
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead?
Funds run by Israel Englander, John Overdeck, and David Siegel bought more than a million shares of Hims & Hers Health in the second quarter. Hims & Hers Health runs a niche telehealth service for people who don't want to ask their regular physician for drugs that carry a lot of social stigma.
2 No-Brainer Growth Stocks to Buy With $200 Right Now
Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.
Why Hims & Hers Health Stock Was Falling This Week
Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.
